Dr. Guy Van Hazel on Selective Internal Radiation Therapy and its Effects on Extrahepatic Colorectal Cancer
Dr. Guy Van Hazel speaks about finding a potential survival advantage for extrahepatic colorectal cancer metastases patients that undergo selective internal radiation therapy.
Guy Van Hazel, MD, Medical Oncologist, Mount Hospital and School of Medicine University of Western Australia, speaks about finding a potential survival advantage for extrahepatic colorectal cancer (CRC) metastases patients that undergo selective internal radiation therapy (SIRT).
Survival data is not yet available. However, for patients that underwent SIRT, time to progression of liver metastases was 7.9 or 8 months; which Van Hazel says is significant and could be indicative of a possible survival benefit in further studies.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
